Ingevity Corporation

NYSE:NGVT

Chemicals - Specialty

Basic Materials
$58.31 +1.13%

+$0.81 today

Market cap
$1.97B
Beta
1.19
P/E (TTM)
-20.0
EPS (TTM)
-$3.62
52W Low $39.74High $79.29

Volume 0.37M

Average 0.26M

NGVT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Ingevity CorporationNYSE: NGVT

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA declines year over year

Q3 FY2026 EBITDA of $51.1M fell 52.9% year over year, behind the -4.9% change in trailing-twelve-month EBITDA. Sequentially, it fell 33.9% from the prior quarter. Over 3 fiscal years it compounded at -56.0% a year.

Context

  • EBITDA amounted to 3.2% of revenue in FY2025, down 20.2 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of $442.88M (+1084.2%) for the fiscal year ending Dec 2026, a step up from the +111.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$51.1M-33.9% QoQ
Last fiscal yearDec 2025
$37.4M+111.4% YoY
LTMSep 2026
$136.5M-4.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-52.9%+223.8%+276.7 pp
1 year+111.4%+1084.2%+972.8 pp
3-year CAGR-56.0%+137.6%+193.7 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
37.4M USD
Year-over-year change
+111.4%
4-year CAGR
-41.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How NGVT compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -4.9% is the 6th highest of 11, against a peer median of +17.1%.
  • EBITDA amounts to 12.1% of revenue for NGVT, versus a peer median of 11.5%.
NGVT Competitors
EBITDA for NGVT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAUCAllied Gold CorporationLTM Jun 2026$444.19M USD+545.7%+27.3%29.8%
ASHAshland Inc.LTM Jun 2026$380M USD+176.5%—20.6%
MTXMinerals Technologies Inc.LTM Apr 2026$368.4M USD+142.5%-20.3%17.3%
KWRQuaker Chemical CorporationLTM Sep 2026$232.84M USD+46.9%+6.3%11.5%
IOSPInnospec Inc.LTM Jun 2026$181M USD-12.7%-7.0%9.8%
NGVTIngevity CorporationLTM Sep 2026$136.5M USD-4.9%-56.0%12.1%
OLNOlin CorporationLTM Jun 2026$74.6M USD-89.6%-36.4%1.1%
ELVRElevra Lithium LimitedFY2025-A$38.8M AUD+88.6%—18.7%
CCThe Chemours CompanyLTM Jun 2026-$166M USD-151.6%-34.7%2.9%
FMCFMC CorporationLTM Mar 2026-$222.5M USD-130.9%—6.5%
SKESkeena Resources LimitedLTM Sep 2026-CA$245.01M CAD-134.8%——
Peer median (excluding NGVT) —+17.1%-13.6%11.5%

Competitors are the stored peer set for NGVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.39B1.67B1.69B1.41B1.17B
Cost of Revenue878.7M1.1B1.22B951.7M706.1M
Gross Profit512.8M570.1M471.9M454.7M461.5M
Gross Margin36.9%34.2%27.9%32.3%39.5%
Research & Development26.3M30.3M31.8M28.1M28.4M
Selling, General & Admin179.3M198.8M183.7M166.7M171.2M
Operating Expenses205.6M229.1M215.5M194.8M199.6M
Depreciation & Amortization109.9M108.8M122.8M108.3M106.4M
EBITDA324.4M440.2M206M(329.5M)37.4M
EBITDA Margin23.3%26.4%12.2%-23.4%3.2%
Operating Income307.2M341M256.4M259.9M261.9M
Operating Margin22.1%20.4%15.2%18.5%22.4%
Interest Income4M5.8M6.3M6.9M4.4M
Interest Expense51.7M61.8M93.3M97.8M77.1M
Other Income / Expenses(144.4M)(71.4M)(266.5M)(795.5M)(404M)
Income Before Tax162.8M269.6M(10.1M)(535.6M)(142.1M)
Pre-Tax Margin11.7%16.2%-0.6%-38.1%-12.2%
Income Tax Expense44.7M58M(4.7M)(105.3M)8.2M
Net Income118.1M211.6M(5.4M)(430.3M)(167.1M)
Net Margin8.5%12.7%-0.3%-30.6%-14.3%
EPS (Basic)2.975.50(0.15)(11.85)(4.61)
EPS (Diluted)2.955.50(0.15)(11.85)(4.61)
Weighted Avg Shares39.8M38.47M36.5M36.32M36.2M
Weighted Avg Shares (Diluted)40.06M38.47M36.5M36.32M36.2M

Ingevity Corporation

NYSE:NGVT

Intrinsic Alpha fair value

Locked

Current Price

$58.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.